335 related articles for article (PubMed ID: 23730262)
21. Perfect match: mTOR inhibitors and tuberous sclerosis complex.
Luo C; Ye WR; Shi W; Yin P; Chen C; He YB; Chen MF; Zu XB; Cai Y
Orphanet J Rare Dis; 2022 Mar; 17(1):106. PubMed ID: 35246210
[TBL] [Abstract][Full Text] [Related]
22. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.
Franz DN; Capal JK
Orphanet J Rare Dis; 2017 Mar; 12(1):51. PubMed ID: 28288694
[TBL] [Abstract][Full Text] [Related]
23. [Subependymal Giant Cell Astrocytoma with Tuberous Sclerosis Complex(TSC-SEGA)].
Ichikawa T; Niida Y
No Shinkei Geka; 2022 Jan; 50(1):111-121. PubMed ID: 35169091
[TBL] [Abstract][Full Text] [Related]
24. Subependymal Giant Cell Astrocytomas in Tuberous Sclerosis Complex-Current Views on Their Pathogenesis and Management.
Gao C; Zabielska B; Jiao F; Mei D; Wang X; Kotulska K; Jozwiak S
J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769603
[TBL] [Abstract][Full Text] [Related]
25. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
[TBL] [Abstract][Full Text] [Related]
26. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
[TBL] [Abstract][Full Text] [Related]
27. New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND).
Gipson TT; Johnston MV
F1000Res; 2017; 6():. PubMed ID: 28663780
[TBL] [Abstract][Full Text] [Related]
28. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
Moavero R; Mühlebner A; Luinenburg MJ; Craiu D; Aronica E; Curatolo P
Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
[TBL] [Abstract][Full Text] [Related]
29. [Tuberous sclerosis complex: A review].
Pfirmann P; Combe C; Rigothier C
Rev Med Interne; 2021 Oct; 42(10):714-721. PubMed ID: 33836894
[TBL] [Abstract][Full Text] [Related]
30. Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy.
Capal JK; Franz DN
Neuropsychiatr Dis Treat; 2016; 12():2165-72. PubMed ID: 27601910
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Everolimus Treatment in Individuals With Tuberous Sclerosis Complex: A Review of the Current Literature.
Tran LH; Zupanc ML
Pediatr Neurol; 2015 Jul; 53(1):23-30. PubMed ID: 26092412
[TBL] [Abstract][Full Text] [Related]
32. Nursing implications for the lifelong management of tuberous sclerosis complex.
Agricola K; Tudor C; Krueger D; Franz DN
J Neurosci Nurs; 2013 Aug; 45(4):226-42. PubMed ID: 23812052
[TBL] [Abstract][Full Text] [Related]
33. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database.
Boggarapu S; Roberds SL; Nakagawa J; Beresford E
Orphanet J Rare Dis; 2022 Sep; 17(1):355. PubMed ID: 36104799
[TBL] [Abstract][Full Text] [Related]
34. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.
Cheng S; Hawkins C; Taylor MD; Bartels U
Pediatr Neurol; 2015 Sep; 53(3):238-242.e1. PubMed ID: 26173783
[TBL] [Abstract][Full Text] [Related]
35. Abnormal serum microRNA profiles in tuberous sclerosis are normalized during treatment with everolimus: possible clinical implications.
Trelinska J; Fendler W; Dachowska I; Kotulska K; Jozwiak S; Antosik K; Gnys P; Borowiec M; Mlynarski W
Orphanet J Rare Dis; 2016 Sep; 11(1):129. PubMed ID: 27680012
[TBL] [Abstract][Full Text] [Related]
36. Clinical management of tuberous sclerosis complex over the lifetime of a patient.
Frost M; Hulbert J
Pediatric Health Med Ther; 2015; 6():139-146. PubMed ID: 29388579
[TBL] [Abstract][Full Text] [Related]
37. An update on the central nervous system manifestations of tuberous sclerosis complex.
Cotter JA
Acta Neuropathol; 2020 Apr; 139(4):613-624. PubMed ID: 30976976
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
39. Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age.
Śmiałek D; Kotulska K; Duda A; Jóźwiak S
Neurol Ther; 2023 Jun; 12(3):931-946. PubMed ID: 37085686
[TBL] [Abstract][Full Text] [Related]
40. Dramatic relapse of seizures after everolimus withdrawal.
Mingarelli A; Vignoli A; La Briola F; Peron A; Giordano L; Banderali G; Canevini MP
Eur J Paediatr Neurol; 2018 Jan; 22(1):203-206. PubMed ID: 28888335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
